New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 23, 2015
08:08 EDTCYHCommunity Health reports agreement for purchase of interest in Metro Health
Subscribe for More Information
07:17 EDTMDCOThe Medicines Co. receives CHMP positive opinions for three products
Subscribe for More Information
January 22, 2015
16:17 EDTKNDGentiva Health stockholders approve combination with Kindred Healthcare
Subscribe for More Information
16:06 EDTKNDGentiva Health stockholders approve combo with Kindred Healthcare
Gentiva Health Services (GTIV) announced that all proposals necessary for the combination with Kindred Healthcare (KND) were approved by Gentiva’s stockholders at the company’s Special Meeting of Stockholders. Gentiva and Kindred expect to complete the transaction on February 2. As previously announced, on October 9, Kindred and Gentiva entered into a definitive agreement under which Kindred will combine with Gentiva for $14.50 per share in cash and 0.257 shares of Kindred common stock based upon an agreed upon fixed exchange ratio.
15:59 EDTXOMAFDA approves Prestalia from Symplmed for treatment of hypertension
Subscribe for More Information
January 21, 2015
11:35 EDTKNDGentiva Health to host special shareholder meeting
Subscribe for More Information
10:28 EDTCVSLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:01 EDTCVSOn the Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTCVS, MDCOOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
07:37 EDTCVSCVS Health initiated with an Overweight at Stephens
Subscribe for More Information
07:25 EDTMDCOThe Medicines Co. upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
06:05 EDTCVSCVS Health upgraded to Buy from Neutral at Goldman
Goldman upgraded CVS to Buy based on strong leverage to Rx growth and Specialty, procurement savings upside, and capital deployment optionality. Price target raised to $113 from $95.
January 20, 2015
11:16 EDTPRGOPerrigo management to meet with B. Riley
Subscribe for More Information
09:02 EDTBAXBaxter receives FDA approval for PHOXILLUM solution
Subscribe for More Information
08:16 EDTBAXMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
07:18 EDTCYHCommunity Health sees Q4 EPS $1.23, consensus $1.20
Sees Q4 net operating revenue approx. $4.9B, consensus $5.06B. Excluding acquisition and integration expenses from the acquisition of Hospital Management Associates, legal expenses related to the HMA legal proceedings underlying the CVR agreement, and expenses related to other government legal settlements, adjusted EBITDA is expected to be approximately $785M for the three months ended December 31, 2014.
07:18 EDTCYHCommunity Health Sees FY14 EPS $3.29, consensus $3.21
Subscribe for More Information
January 16, 2015
10:47 EDTKND, CYHBofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
10:06 EDTMDCOHigh option volume stocks
Subscribe for More Information
January 14, 2015
07:37 EDTKNDJPMorgan to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use